MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs
January 03 2023 - 4:05PM
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading commercial
cell-engineering company providing enabling platform technologies
to advance innovative cell-based research, as well as
next-generation cell therapeutic discovery, development and
commercialization, today announced the signing of a strategic
platform license (SPL) with Catamaran Bio, Inc., a biotechnology
company developing novel, off the-shelf chimeric antigen receptor
(CAR)-NK cell therapies to treat a broad range of cancers, with a
primary focus on solid tumors.
Under the terms of the agreement, Catamaran obtains
non-exclusive clinical and commercial rights to use MaxCyte’s Flow
Electroporation® technology and ExPERT™ platform. In return,
MaxCyte will receive platform licensing fees and program-related
revenue.
“The ability to leverage synthetic biology to engineer cell
therapies will help drive innovative solutions for solid tumor
cancer treatment. At MaxCyte, we are passionate about driving the
discovery, development and manufacturing of next-generation,
cell-based medicines to tackle complex diseases and cancer,”
said Doug Doerfler, President and CEO of MaxCyte.
“We are excited to support Catamaran with the advancement of their
pipeline of differentiated CAR-NK cell therapies into and through
the clinic.”
Catamaran is currently using synthetic biology and non-viral
cell engineering to develop highly potent allogeneic, cryopreserved
CAR-NK cell therapies capable of treating challenging cancers,
including solid tumors, by combining new functional attributes with
the inherent cancer-fighting properties of NK cells. The company
has developed its TAILWIND® platform, an integrated suite of
technologies, to engineer, expand and process NK cells into safe
and effective, off-the-shelf cell therapy products for multiple
cancer types.
MaxCyte’s ExPERT™ instrument portfolio is the next generation of
leading, clinically-validated electroporation technology for
complex and scalable cell engineering. By delivering high
transfection efficiency, seamless scalability and enhanced
functionality, the ExPERT™ platform delivers the high-end
performance essential to enabling the next wave of biological and
cellular therapeutics. The Catamaran agreement is MaxCyte’s 19th
SPL overall.
About MaxCyteMaxCyte is a leading,
cell-engineering focused company providing enabling platform
technologies to advance the discovery, development and
commercialization of next-generation cell therapeutics and to
support innovative, cell-based research. Over the past 20 years, we
have developed and commercialized our proprietary Flow
Electroporation® technology, which facilitates complex engineering
of a wide variety of cells. Our ExPERT™ platform, which is based on
our Flow Electroporation technology, has been designed to support
the rapidly expanding cell therapy market and can be utilized
across the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx®, STx® GTx® and VLx™;
a portfolio of proprietary related processing assemblies or
disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio. Learn more at
maxcyte.com and follow us on Twitter and LinkedIn.
About Catamaran BioCatamaran Bio is
developing novel, off-the-shelf chimeric antigen receptor (CAR)-NK
cell therapies designed to treat a broad range of cancers,
including solid tumors. The company’s proprietary capabilities
enable it to harness the natural cancer-fighting properties of NK
cells and enhance and tailor their effectiveness with the power of
synthetic biology and innovative non-viral cell engineering.
Catamaran uses its TAILWIND® platform, an integrated suite of
technologies, to specifically address the end-to-end methods of
engineering, processing and manufacturing NK cells and rapidly
advance its pipeline of CAR-NK cell therapy programs. The company’s
team combines experienced biopharmaceutical leadership with
founding scientists who are pioneers in NK cell biology,
engineering, manufacturing and clinical application. Catamaran is
backed by leading financial and corporate investors, including SV
Health Investors, Sofinnova Partners, Lightstone Ventures, Takeda
Ventures, Astellas Venture Management, and the UMN Discovery
Capital investment program. For more information, please
visit catamaranbio.com and follow Catamaran
on LinkedIn and @CatamaranBio on Twitter.
MaxCyte Contacts:
US IR AdviserGilmartin
GroupDavid Deuchler, CFA+1 415-937-5400ir@maxcyte.com
US Media RelationsSpectrum Seismic
CollaborativeValerie Enes+1
408-497-8568valerie@spectrumscience.com
Nominated Adviser and Joint Corporate
BrokerPanmure GordonEmma Earl / Freddy
CrossleyCorporate BrokingRupert Dearden+44 (0)20 7886 2500
UK IR AdviserConsilium Strategic
CommunicationsMary-Jane ElliottChris Welsh+44 (0)203 709
5700maxcyte@consilium-comms.com
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jul 2023 to Jul 2024